History repeating: guidelines to address common problems in psychedelic science

Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and...

Full description

Saved in:
Bibliographic Details
Main Authors: Michiel van Elk (Author), Eiko I. Fried (Author)
Format: Book
Published: SAGE Publishing, 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_26f57c728f5d4b62bd92d2c20f756945
042 |a dc 
100 1 0 |a Michiel van Elk  |e author 
700 1 0 |a Eiko I. Fried  |e author 
245 0 0 |a History repeating: guidelines to address common problems in psychedelic science 
260 |b SAGE Publishing,   |c 2023-09-01T00:00:00Z. 
500 |a 2045-1261 
500 |a 10.1177/20451253231198466 
520 |a Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the validity of core findings and raise doubt regarding clinical efficacy and safety. In this paper, we introduce the 10 most pressing challenges, grouped into easy, moderate, and hard problems. We show how these problems threaten internal validity (treatment effects are due to factors unrelated to the treatment), external validity (lack of generalizability), construct validity (unclear working mechanism), or statistical conclusion validity (conclusions do not follow from the data and methods). These problems tend to co-occur in psychedelic studies, limiting conclusions that can be drawn about the safety and efficacy of psychedelic therapy. We provide a roadmap for tackling these challenges and share a checklist that researchers, journalists, funders, policymakers, and other stakeholders can use to assess the quality of psychedelic science. Addressing today's problems is necessary to find out whether the optimism regarding the therapeutic potential of psychedelics has been warranted and to avoid history repeating itself. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Psychiatry 
690 |a RC435-571 
655 7 |a article  |2 local 
786 0 |n Therapeutic Advances in Psychopharmacology, Vol 13 (2023) 
787 0 |n https://doi.org/10.1177/20451253231198466 
787 0 |n https://doaj.org/toc/2045-1261 
856 4 1 |u https://doaj.org/article/26f57c728f5d4b62bd92d2c20f756945  |z Connect to this object online.